在URD-PBSCT后降低了细胞巨病毒的活性和病毒性血,但没有增加GVHD:使用向ATG剂量策略的前性研究
Sheng Chen1, Lu Wang2, Songhua Luan3
1Medical School of Chinese PLA, Beijing 100083, China.
Cancer pathogenesis and therapy
|February 2, 2026
概括
在与无关的捐赠者外周血液干细胞移植 (URD-PBSCT) 中,一种新的抗胸细胞球蛋白 (ATG) 剂量策略降低了细胞巨血病毒 (CMV) 的重新激活. 这种有针对性的方法改善了结果,但没有增加移植与宿主疾病 (GVHD) 的风险.
科学领域:
- 造血干细胞移植 造血干细胞移植
- 免疫抑制疗法是一种免疫抑制疗法.
- 移植与宿主疾病的预防 移植与宿主疾病的预防
背景情况:
- 抗胸细胞球蛋白 (ATG) 对于预防移植对宿主疾病 (GVHD) 和在全源造血干细胞移植 (allo-HCT) 中的移植失败至关重要.
- 不足或过度的ATG暴露都会带来风险,影响疗效并增加诸如病毒活性和非复发性死亡率之类的并发症.
- 优化ATG剂量对于改善alo-HCT患者的治疗结果至关重要.
研究的目的:
- 评估一种新型ATG向剂量策略的疗效和安全性,用于接受非捐赠者外周血液干细胞移植 (URD-PBSCT) 的患者.
- 确定ATG度的治疗药物监测是否可以优化剂量和改善临床结果.
- 为了将目标ATG剂量的结果与使用固定剂量的历史数据进行比较.
主要方法:
- 一项前性单臂研究招募了30名接受URD-PBSCT的患者,基于度监测的4天ATG向剂量策略.
- 在3日和2日进行剂量调整,以达到活性ATG的度-时间曲线 (AUC) 下的最佳面积.
- 分析了包括移植,病毒感染 (CMV,EBV),急性和慢性GVHD,复发和存活率在内的结果,并与接受固定ATG剂量的38名患者的历史队列进行了比较.
主要成果:
- 目标剂量队列成功地实现了100%的捐赠者嵌合体移植.
- 与历史队列相比,观察到细胞巨乳病毒 (CMV) 反激活的累积发病率 (30.0%与78.9%) 和持续的CMV病毒病率 (16.7%与42.1%) 显著较低 (分别P <0.001和P = 0.026).
- 在埃普斯坦-巴尔病毒 (EBV) 再激活,急性或慢性GVHD发病率,复发或队列之间的生存率方面没有发现显著差异.
结论:
- 一个有针对性的ATG剂量策略有效地减少了URD-PBSCT患者的CMV活性和病毒性.
- 这种方法优化了免疫抑制,在不影响安全或增加GVHD风险的情况下实现了理想的临床结果.
- 有针对性的ATG剂量代表了URD-PBSCT的一个有希望的进步,提高了患者的管理和生存率.
更多相关视频
相关概念视频
Bioavailability Study Design: Single Versus Multiple Dose Studies
243
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
243
Increasing Function
394
An increasing function exhibits a rise in output values as input values increase. This behavior is depicted graphically as a curve or line that slopes upward from left to right. Such a function satisfies the condition that if x1 < x2, then f(x1) < f(x2), indicating that the function values grow with increasing inputs. This concept is fundamental in understanding growth trends across various domains, such as population dynamics, financial investments, or resource consumption.The...
394
Dose Size and Dosing Frequency: Determination Methods
302
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
302
Reducing Line Loss
390
In a three-phase circuit, line loss is an indicator of energy dissipated as heat due to the resistance of transmission lines. To address this, incorporating transformers into the system—a step-up transformer at the source and a step-down transformer at the load—is a strategic solution. Two three-phase transformers are introduced to improve this.
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
390
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
238
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
238
Increased Body Temperature
7.5K
A body temperature above 38°C (100.4 °F) is known as fever or pyrexia, and a person with fever is termed 'febrile.' Typically, the hypothalamus, a part of the brain that acts as the body's thermostat, regulates body temperature through a thermoregulatory setpoint. It receives signals from cold and warm thermal receptors throughout the body and adjusts the body's temperature accordingly. Fever occurs when this hypothalamic setpoint is altered, usually in...
7.5K


